Adaptimmune Therapeutics PLC (NASDAQ: ADAP) is one of 282 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Adaptimmune Therapeutics PLC to similar businesses based on the strength of its earnings, valuation, profitability, risk, analyst recommendations, institutional ownership and dividends.

Institutional & Insider Ownership

68.2% of Adaptimmune Therapeutics PLC shares are held by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 24.5% of Adaptimmune Therapeutics PLC shares are held by company insiders. Comparatively, 17.2% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Adaptimmune Therapeutics PLC and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Adaptimmune Therapeutics PLC $14.20 million -$71.57 million -10.69
Adaptimmune Therapeutics PLC Competitors $286.20 million $34.74 million 139.18

Adaptimmune Therapeutics PLC’s competitors have higher revenue and earnings than Adaptimmune Therapeutics PLC. Adaptimmune Therapeutics PLC is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Adaptimmune Therapeutics PLC and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adaptimmune Therapeutics PLC 0 1 3 0 2.75
Adaptimmune Therapeutics PLC Competitors 800 3160 11457 229 2.71

Adaptimmune Therapeutics PLC currently has a consensus target price of $12.50, indicating a potential upside of 55.86%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.84%. Given Adaptimmune Therapeutics PLC’s stronger consensus rating and higher possible upside, analysts plainly believe Adaptimmune Therapeutics PLC is more favorable than its competitors.

Profitability

This table compares Adaptimmune Therapeutics PLC and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adaptimmune Therapeutics PLC -138.46% -27.99% -21.47%
Adaptimmune Therapeutics PLC Competitors -5,328.41% -476.49% -40.20%

Summary

Adaptimmune Therapeutics PLC beats its competitors on 8 of the 11 factors compared.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.